The University of Texas MD Anderson Cancer Center was awarded a 5-year, $678,515 Project Grant from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) to evaluate novel PET imaging and liquid biopsy approaches to predict response and recurrence in hepatocellular carcinoma (liver cancer) patients undergoing Y-90 radioembolization therapy. The project aims to assess the utility of 18F-FSPG PET/CT imaging to detect treatment-resistant disease earlier than standard-of-care imaging, and to determine if circulating tumor DNA (ctDNA) levels correlate with PET findings and clinical outcomes. The overarching goal is to develop improved methods to guide therapy decisions and monitor disease status in liver cancer patients receiving this locoregional treatment.
Generated 1/28/25, 9:54 AM